Peripapillary subretinal neovascular membranes: A review

Lee, Jimin; Ferrucci, Steven

doi:10.1016/j.optm.2011.04.104

Cited by 6 publications

(3 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The pathogenesis of peripapillary CNVM in patients with papilledema due to IIH is unclear, but it seems to be different from CNVMs that occur in other posterior segment diseases such as exudative age-related macular degeneration (16)(17)(18)(19). In macular degeneration, retinal pigment epithelium dysfunction and Bruch membrane breaks occur as a result of retinal drusen deposition and inflammation, which subsequently promotes hypoxia and angiogenesis (19,20).…”

Section: Discussionmentioning

confidence: 99%

“…In macular degeneration, retinal pigment epithelium dysfunction and Bruch membrane breaks occur as a result of retinal drusen deposition and inflammation, which subsequently promotes hypoxia and angiogenesis (19,20). Peripapillary CNVM in IIH might result from a pressure deformity of the Bruch membrane at the level of the optic nerve head (16). This combined with persistent hypoxic environment created by axonal swelling may initiate the angiogenesis cascade, leading to the neovascular membrane formation (21,22).…”

Section: Discussionmentioning

confidence: 99%

“…Management options for peripapillary CNVM in patients with IIH include observation, subretinal surgery, laser photocoagulation, photodynamic therapy, or intravitreal injection of anti-VEGF agents (3,6,16,23,24). Although therapeutic decisions must be made on a case-by-case basis, the use of anti-VEGF agents currently is the method of choice (1,7,23,24).…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Management of Peripapillary Choroidal Neovascular Membrane in Patients With Idiopathic Intracranial Hypertension

Özgönül

Moinuddin

Munie³

et al. 2019

Journal of Neuro-Ophthalmology

View full text Add to dashboard Cite

OBJECTIVE To report the clinical features and treatment outcomes of patients with peripapillary choroidal neovascular membrane (CNVM) secondary to idiopathic intracranial hypertension (IIH). METHODS Retrospective, multicenter chart review of patients diagnosed with peripapillary CNVM in the course of the treatment and follow-up of IIH. RESULTS Records were reviewed from 7 different institutions between 2006 and 2016. Ten patients (13 eyes) with a diagnosis of IIH and at least 3 months of follow-up developed CNVM. Three of the total 10 patients developed bilateral CNVM. The mean time from the diagnosis of IIH to CNVM diagnosis was 41 months. Mean follow-up period was 8 months after diagnosis of CNVM. All patients were treated with acetazolamide for IIH. Seven eyes were observed, and 6 eyes were given anti-vascular endothelial growth factor (anti-VEGF) injections, including bevacizumab, ranibizumab, and aflibercept. All CNVMs regressed with subretinal fibrosis, and visual acuity improved in most patients. Papilledema resolved in only 1 eye, while the other 12 eyes had persistent papilledema at last follow-up. CONCLUSIONS Peripapillary CNVM, a rare complication of IIH, often resolves spontaneously with treatment of IIH. In vision-threatening and/or persistent cases, intravitreal anti-VEGF treatment may be a safe and effective therapeutic option.

show abstract